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Breast cancer diagnosed during pregnancy is associated with
enrichment of non-silent mutations, mismatch repair deﬁciency
signature and mucin mutations
Bastien Nguyen 1, David Venet1, Hatem A. Azim Jr 1,2, David Brown 1,3, Christine Desmedt1, Matteo Lambertini 1, Samira Majjaj1,
Giancarlo Pruneri4, Fedro Peccatori5, Martine Piccart1, Françoise Rothé1 and Christos Sotiriou1
Breast cancer diagnosed during pregnancy (BCP) is a rare and highly challenging disease. To investigate the impact of pregnancy
on the biology of breast cancer, we conducted a comparative analysis of a cohort of BCP patients and non-pregnant control
patients by integrating gene expression, copy number alterations and whole genome sequencing data. We showed that BCP
exhibit unique molecular characteristics including an enrichment of non-silent mutations, a higher frequency of mutations in mucin
gene family and an enrichment of mismatch repair deﬁciency mutational signature. This provides important insights into the
biology of BCP and suggests that these features may be implicated in promoting tumor progression during pregnancy. In addition,
it provides an unprecedented resource for further understanding the biology of breast cancer in young women and how pregnancy
could modulate tumor biology.
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INTRODUCTION
Breast cancer is the most frequently diagnosed malignancy during
pregnancy.1 Its incidence is increasing given the rising trend of
delayed childbearing.2 Given its rarity, few dedicated studies were
performed so far; hence, our understanding of these tumors
remains poor. The clinical management of these patients follows
standard guidelines with only minor adaptations according to
gestational age, maternal wishes and fetal considerations.2
Therefore, the molecular characterization of BCP goes beyond
academic curiosity as it is of utmost clinical interest to determine if
these patients should be treated similarly to non-pregnant breast
cancer patients. In this report, we aimed to identify speciﬁc
molecular alterations characterizing BCP by combining whole
genome sequencing, copy number alteration and gene expression
data.
RESULTS
A total of 167 patients with primary breast cancer were
retrospectively included in this study, 54 of whom were diagnosed
during pregnancy. Detailed patient characteristics were previously
published.3 At a median follow-up of 9 years, median disease-free
survival (DFS) time of BCP was 9.8 years vs. 12.5 years in controls
(P= 0.041, log rank test, Supplementary Fig. S1a). Observed 5-year
overall survival (OS) rate was 95.5% vs. 85.1% in BCP and control,
respectively; median OS time was not reached within the time
frame of the study (Supplementary Fig. S1b). In a multivariable
Cox proportional hazards regression of DFS and OS, adjusted for
age at diagnosis, date of diagnosis, pathological stage and
molecular subtypes by IHC, we found that BCP was associated
with worse DFS (multivariable hazard ratio [mHR] 1.81; 95% CI
1.09–3.01, P= 0.024) and OS (mHR 2.53; 95% CI 1.20–5.36, P=
0.017) (detailed survival data is provided in Supplementary Table
S1).
BCP and controls have similar somatic copy number alteration
proﬁles
We ﬁrst sought to investigate whether tumors from BCP patients
show distinct copy number alterations (CNAs) compared to
tumors from matched non-pregnant breast cancer patients
(controls). Hence, we performed genome-wide copy number
alterations proﬁling on 160 formalin-ﬁxed parafﬁn-embedded
(FFPE) primary tumor samples from 52 BCP patients and 108
controls. Of note, gene expression data were available for all
patients as previously described.4 After quality control, CNA
proﬁles were obtained for 125 tumor samples (78%) from 38 BCP
and 87 controls. The main reason for exclusion was low cancer cell
fraction (CCF < 30%) as estimated with the Genome Alteration
Print algorithm5 (Supplementary Fig. S2). No differences in
clinicopathological features were observed between BCP and
controls (Supplementary Table S2). We found no signiﬁcant
differences between BCP and controls in terms of cancer cell
fraction, ploidy, and fraction of genome altered (Fig. 1a-c).
Moreover, no signiﬁcant differences were observed between the
CNA proﬁles of the two groups neither at the segment nor at the
chromosome arm levels, including the gains of 1q and 8q and loss
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of 8p, reported to frequently occur in breast cancer6 (Fig. 1d). We
also compared CNAs proﬁles by intrinsic subtypes as deﬁned by
PAM50 and found no signiﬁcant differences (Supplementary Fig.
S3 and Supplementary Table S3).
We next focused our analysis on the 35 genes that were
previously identiﬁed as CNA drivers in breast cancer.7 As expected,
MYC oncogene was the most frequently gained/ampliﬁed whereas
TP53 tumor suppressor gene was the most frequently lost/deleted
across the whole cohort (Fig. 1e). Using GISTIC2.0,8 we identiﬁed
22 focal ampliﬁcations and 23 focal deletions and found no
differences between their prevalence in the two groups
(Supplementary Fig. S4). Taken together, these results suggest
that the CNA proﬁles of BCP and controls are similar.
BCP shows a higher number of non-silent mutations
To identify potential genomic differences between BCP patients
and controls, we performed whole genome sequencing (WGS) on
paired DNA samples extracted from FFPE blocks (i.e., primary
tumors and histologically normal axillary lymph nodes) in a subset
of 53 breast cancer patients from our initial series, 35 of whom
were BCP (Supplementary Fig. S2 and Supplementary Table S2).
We achieved 32X and 19X median haploid genome coverage for
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Fig. 1 Summary of the genome-wide copy number analysis of 87 controls and 38 BCP tumor samples. a–c Comparison of cancer cell fraction,
ploidy and fraction of genome altered between controls and BCP. d Comparison of the CNA frequencies of controls (blue) and BCP (pink). e
Heatmap of 35 CNA breast cancer driver genes according to their alterations; controls (blue) and BCP (pink). P, p-value derived for the
Mann–Whitney U test
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tumor and normal samples respectively, which is similar in range
to previous studies7 (Supplementary Fig. S5). We detected a
median of 13,829 and 10,084 single nucleotide variants (SNVs) and
a median of 21 and 26 small insertions and deletions (Indels) in
BCP and controls, respectively, and found no difference between
the two groups (Fig. 2a and Supplementary Fig. S6a-c). Moreover,
there was no difference in structural variations (insertions,
deletions, duplications) nor tumor heterogeneity as assessed by
the MATH score9 (Supplementary Fig. S6d-f).
We identiﬁed a median of 14 non-silent mutations per tumor
which is comparable to another large-scale breast cancer cohort
study7 (Supplementary Table S4). Interestingly, BCP had a
signiﬁcantly higher number of non-silent mutations than controls
(median: 20 vs. 12, P= 0.027, Fig. 2b and Supplementary Fig. S6g-
h). This observation remained consistent after correcting for
potential confounding factors including age at diagnosis, date of
diagnosis, pathological stage and molecular subtypes by IHC (P=
0.019, Fig. S6g). Compared to controls, BCP had also a signiﬁcantly
higher number of mutations previously reported in breast cancer
in the Catalog of Somatic Mutations in Cancer (COSMIC)
database10 (P= 0.018, Supplementary Fig. S6i). At the gene level,
we identiﬁed 17 genes harboring at least one non-silent mutation
with a frequency of at least 5% across all patients. Of those, TP53
and PIK3CA were the most frequently mutated genes without any
signiﬁcant difference between the two groups (Fig. 2c).
BCP is associated with a higher frequency of mutations in mucin
gene family
MUC17 was the third most mutated gene and four other mucin
gene family members namely MUC2, MUC4, MUC12, and MUC20,
were among the most frequently mutated genes in BCP (Fig. 2c).
Within the mucin gene family, we identiﬁed 20 missense
mutations and one nonsense mutation in BCP compared to only
two missense mutations in controls. Among these 20 mucin
variants, 10 were present in the COSMIC database,10 which was
higher than expected by chance (P= 0.006, Monte-Carlo test,
Supplementary Table S4). Altogether, we found a signiﬁcantly
higher number of BCP with non-silent mutations in the mucin
gene family compared to controls (45.7 vs. 11.1% respectively, P=
0.015, Fig. 2c). This observation remained consistent after
correcting for classical clinicopathological features (P= 0.008).
Similar ﬁndings were observed by comparing BCP with 56
matched controls taken from the TCGA dataset (45.7 vs. 23.1%
respectively, P= 0.034). Acknowledging that some mucins (MUC4,
MUC16) are known to give rise to false positive calls due to
technical artifacts,11 we removed these two genes and conﬁrmed
the above-mentioned results (37.1 vs. 5.5%, P= 0.020 and 37.1 vs.
14.3%, P= 0.020, using controls and TCGA controls, respectively).
We did not ﬁnd any differences in clinicopathological features
or survival according to mucin mutational status (Supplementary
Table S5 and Supplementary Fig. S7). There were three hotspots
mutations (i.e., present in two distinct patients) two in MUC17 and
one in MUC20, and ﬁve missense mutations were clustered within
260 base pairs of MUC2 (Fig. 3a). None of these mutations were in
annotated protein domains. Since the glycosylation of mucins is
known to play a major role in producing a chemical barrier at the
epithelium of tubular organs for protection and lubrication, we
interrogated whether these mutations could affect glycosylation
acceptor sites. The mucin O-glycosylation is characterized by the
addition of N-acetylgalactosamine (GalNAc) to the hydroxyl group
of serine or threonine residues.12 Remarkably, 40.9% of missense
mutations affecting mucins resulted in an amino acid change to a
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Fig. 2 Mutational landscape of individual BCP and controls. a Bar chart representing the absolute number of substitutions in BCP and
controls, y-axis limited to 50,000 indicated by (*). b Bar chart representing the absolute number of non-silent mutations in BCP and controls
(median: 20 vs. 12, P= 0.027, respectively). c Co-mutation plot showing genes harboring at least one non-silent mutation with a frequency of
at least 5% across the whole cohort, and their corresponding frequencies in BCP and controls (right). d Proportion of breast cancer
substitution signatures in each sample. Signatures are colored according to broad biological groups: 1 and 5 are associated with clock-like
processes, 2 and 13 are APOBEC-related, 20 and 26 are associated with mismatch-repair deﬁciency, 3 and 8 are associated with homologous-
recombination deﬁciency
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serine residue, which was signiﬁcantly higher than expected by
chance (P= 0.0002, Monte-Carlo test), suggesting mucin hyper-
glycosylation in BCP. We also found that the frequency of
missense mutations resulting in a gain of serine site in mucins
in the TCGA dataset was signiﬁcantly lower compared with BCP
(6.3% in TCGA vs. 40.9% in BCP, P < 0.001). Since mucins
expression is known to increase throughout gestation in mice,13
we expected that mucins were also upregulated in BCP. We
therefore derived a metagene signature comprising all members
of the mucin gene family (called “MUCsig”) from the correspond-
ing gene expression data and found higher expression of MUCsig
in BCP than in controls (P= 0.017, Fig. 3b-c). Altogether, these
results show that BCP is associated with an increased expression
of mucins as well as a higher frequency of mutations in mucin
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Fig. 3 Enrichment of mucin mutations and upregulation in BCP. a Lollipop plots were generated using cBioPortal Mutation Mapper. Each
lollipop denotes a unique missense mutation for MUC2, MUC17, and MUC20 in BCP. b MUCsig according to normal adult mouse mammary
development (from pregnancy day 1 to involution day 2). c Comparison of MUCsig between controls and BCP. P, p-value derived for the
Mann–Whitney U test
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gene family that may potentially lead to mucin
hyperglycosylation.
BCP is enriched in mutational signature related to mismatch repair
deﬁciency
To have a better understanding of the etiology of BCP, we
interrogated the contribution of base-substitution signatures
known to occur in breast cancer.7 When evaluating the proportion
of each signature present in each sample, we found that signature
1 was more prevalent in BCP compared to controls whereas
signature 5 was more prevalent in controls (P= 0.013, FDR= 0.053
and P= 0.01, FDR= 0.053, respectively, Fig. 2d). These results
remained consistent after controlling for clinicopathological
features (P= 0.002, FDR= 0.014 and P= 0.004, FDR= 0.016,
respectively). When evaluating the presence or absence of
mutational signatures we found that signature 20 (Sig20) was
found in 13 out of 35 BCP (37.1%), as compared to only 2 out of 18
controls (11.1%) (P= 0.059, FDR= 0.410, Fig. 2d). When control-
ling for clinicopathological features, this observation was sig-
niﬁcant (P= 0.004, FDR= 0.029). Signature 1 is known to be
associated with age at diagnosis while the etiology of signature 5
is still unclear. Sig20, previously found in stomach and breast
cancers, is related to DNA mismatch repair (MMR) deﬁciency.14 Of
interest, this signature remained signiﬁcantly enriched in BCP
when increasing the number of controls with 64 matched cases
derived from the BRCA560 dataset (37.1 vs. 3.1%, P < 0.001). No
classical clinicopathological features were associated with BCP
Sig20-positive tumors except progesterone receptor negative
status (Supplementary Table S6). We found that Sig20 frequency
was strongly correlated with SNV mutational load (ρ= 0.56, P <
0.001, Supplementary Fig. S8a) with Sig20-positive tumors
harboring a median of 31,632 SNVs, as compared to 7,352 SNVs
in Sig20-negative tumors (P < 0.001, Fig. 4a). Next, we interrogated
if Sig20 could be caused by alteration of genes involved in the
MMR machinery either at the expression or copy number levels.
The ﬁrst step of MMR is the recognition of replication errors
mediated by MutS homolog complexes; MSH2 and MSH6.15 We
found a signiﬁcantly lower expression of MSH2 in patients
harboring Sig20 (P= 0.047, Fig. 4b) corroborated by a negative
correlation between MSH2 expression and Sig20 frequency (ρ=
−0.27, P= 0.024, Supplementary Fig. S8b). This could be partially
caused by CNA in MSH2 since 5 out of 15 Sig20-positive versus 1
out of 38 Sig20-negative tumors harbored MSH2 deletions (33.3 vs.
2.6%, P= 0.01). Finally, we interrogated the impact of Sig20 on
survival and found that BCP Sig20-positive patients had a shorter
DFS than BCP Sig20-negative patients (median DFS time of 2.9
years vs. 10.2 years respectively P= 0.091, log rank test, Fig. 4c). In
Sig20-positive patients the median OS was 6.72 years while the
median OS was not reached in BCP Sig20-negative patients (P=
0.009, log rank test, Supplementary Fig. S9). This was not
signiﬁcant in a multivariate model (DFS mHR 1.06; 95% CI
0.21–4.27, P= 0.31; OS mHR 0.8; 95% CI 0.12–5.07, P= 0.81,
respectively). Overall, these results suggest that some BCP patients
show a defective MMR due to copy number loss of MSH2.
DISCUSSION
This study reveals important molecular differences characterizing
BCP that may potentially represent a biologic explanation for their
rather aggressive clinical behavior. First, BCP was enriched in non-
silent mutations that could have potential oncogenic functiond.
Second, 45% of BCP harbored a mutation in mucin gene family in
addition to an upregulation of mucins at the mRNA level. Like in
mice,13 this could be due to physiological change induced by
pregnancy to prepare the breast for lactation. Our hypothesis is
that some preexisting subclones carrying mucin mutations could
have a growth advantage under pregnancy state. Another
argument in favor of this hypothesis is the fact that most mucin
mutations resulted in an amino acid change to a serine residue
and that some of them are in hotspot regions. It has been
previously found that in breast cancer, alterations in mucin
expression or glycosylation inﬂuence tumor growth, adhesion,
invasion, and immune surveillance.16,17 The impact of missense
mutations resulting in an amino acid change to a serine residue on
the glycosylation status of mucins is unknown, but it is tempting
to speculate that these alterations could inﬂuence their function,
stability and secretion. More investigations are required to
determine the exact effect of mucin mutations in BCP and in
breast cancer in general, but these alterations could play a role in
BCP biology.
Moreover, BCP showed a higher prevalence of signatures 1 and
20 and a lower prevalence of signature 5. The etiology of signature
5 is not well understood.18 The high prevalence of signature 1
cannot be explained by a difference in age at diagnosis or age of
the blocks since similar results were found in a multivariate
analysis after adjusting for both variables. 37.1% of BCP were
associated with signature 20 (Sig20), attributable to DNA
mismatch repair deﬁciency. This is surprising given the low
frequency (1–2%) of MMR deﬁciency recently reported in breast
cancer.19 Mechanistically, this could be explained in part by the
deletion of MSH2, a key gene involved in MMR. Survival analysis
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showed that BCP Sig20-positive patients had the worst prognosis
whereas BCP Sig20-negative patients had DFS comparable to
controls. MMR deﬁciency and high mutational burden have been
shown to predict clinical beneﬁt to immune checkpoint blockade
in colorectal and other types of highly immunogenic cancers.20,21
To date, the role of checkpoint inhibitors in the treatment of
breast cancer is under intensive investigation and the results are
still awaited.22 While the feasibility of investigating new agents in
such peculiar disease is rather complex, these results could
potentially open the door to identify high-risk BCP patients who
could beneﬁt from immunotherapy.
A potential limitation of our study is that we used archived FFPE
samples that are known to be challenging for WGS due to DNA
degradation and induction of artefacts. Indeed, the higher
proportion of signature 1 and 5 observed in our study could be
due to C > T artefacts induced by formalin ﬁxation. Nonetheless,
BCP and controls were processed in the same way with no
difference in the age of the blocks and the sequencing coverage
reached in normal and in tumor tissues was comparable to other
studies.7 Another limitation of our study is the lack of epigenetic
proﬁling analysis. As it is known that pregnancy induce epigenetic
changes in epithelial cells to support mammary development,23
we can hypothesize that these modiﬁcations could impact breast
cancer biology. Therefore, the study of such modiﬁcations in BCP
is worthy further investigation. In conclusion, we believe that our
work provides important insights into the biology of BCP and a
unique resource to study the biology of breast cancer in young
women and how pregnancy could modulate tumor biology.
METHODS
Patients and samples
A total of 167 patients with primary breast cancer were retrospectively
included in this study, 54 of whom were diagnosed during pregnancy. All
patients were diagnosed and followed up at the European Institute of
Oncology (IEO, Milan, Italy) from 1996 to 2010. As previously described,3
this is a case-control study, in which pregnant breast cancer patients and
controls were matched according to age, tumor size, nodal status, and date
of diagnosis. For the current genomic analysis, we opted to exclude
patients who received neoadjuvant therapy to avoid potential impact of
treatment on the obtained results. The majority were treated with
anthracycline-based regimen (individual patients data are presented in
Supplementary Table S1). All patients had available FFPE tissue from the
primary tumor resection and there was only one tumor sample per patient.
All control patients were pre-menopausal at time of diagnosis. ER/PR-status
were deﬁned by ASCO-CAP. For the classiﬁcation of Luminal A and B we
used a cut-off of Ki67 > 20% according to the St Gallen 2015 Consensus
Meetings.24 Matched normal tissues were collected from histologically
conﬁrmed tumor-free axillary lymph nodes or tumor-adjacent normal
tissue and there was only one normal sample per patient. FFPE tissue
sections were deparafﬁnized by xylene followed by a 100% ethanol wash.
DNA extraction was performed using the QIAamp DNA FFPE Tissue Kit
(Qiagen, Hilden, Germany) following the manufacturer’s recommendations.
The quantity of double-stranded DNA was evaluated using the Qubit
dsDNA BR Assay Kit. For the WGS, we selected 18 control patients based on
major clinicopathological features of the 35 BCP patients, namely age at
diagnosis, ER status, and grade. All patients provided written informed
consent for the use of tissue samples for research purposes as per the IEO
institutional policies. This study was approved by the Ethics Committee of
Institut Jules Bordet (Number 1782). The validation of the enrichment of
mutations in the mucin family genes in BCP were done by comparing the
frequency of these mutations in BCP patients with putatively non-pregnant
patients retrieved from the TCGA dataset25 and selected to have similar
age, estrogen receptor (ER) and progesterone receptor (PR) distribution (N
= 56) (Supplementary Table S7). The validation of the enrichment of
signature 20 in BCP were done by comparing the frequency of this
signature in BCP patients with putatively non-pregnant patients retrieved
from the 560 breast cancer dataset7 (referred to as BRCA560) and selected
to have similar age, ER and PR distribution (N= 64).
Transcriptomic proﬁling
All samples were hybridized on Affymetrix Human Genome U219 array
plates following the manufacturer’s protocol, as described before.4 The
metagene signature MUCsig was calculated by taking the mean expression
level of all genes present in the mucin family, scaled to a standard
deviation of one and centered around zero. The publicly available murine
data set derived from normal breast of pregnant mice (GEO ID: GSE819113)
was used to evaluate mucin expression in the normal breast during
pregnancy. Ensembl database was used to convert mouse gene names to
the human equivalent.
Genome-wide copy number analysis
Hematoxylin and eosin slides from the archived FFPE blocks were reviewed
by a pathologist (G.P.) to conﬁrm diagnosis and evaluate tumor content.
Samples with tumor purity below 60% were macrodissected (N= 56). DNA
was extracted as described above. A total of 80 ng of DNA was used for
copy number proﬁling using the Affymetrix OncoScan® FFPE Assay Kit
according to the manufacturer’s instructions. The raw intensity values from
the scanned chips were normalized to obtain Log2 ratios, B allele
frequencies and genotyping calls (AA/AB/BB) using Affymetrix Power Tools.
We used release NA.33 of the NetAffx library for the reference model and
annotation. We computed the median absolute pairwise deviation and the
median auto-correlation from the normalized log2 ratios as quality control
metrics and used a threshold of 0.30 and 0.5, respectively, to ﬂag failed
arrays. Further details are provided in the Supplementary Methods.
Library preparation and whole genome sequencing
For each of 53 patients, two samples of 1μg genomic DNA from tumor and
histologically normal axillary lymph nodes were whole genome sequenced
at The McDonnell Genome Institute at Washington University (St Louis MO,
USA) on an Illumina HiSeqX platform. Brieﬂy, manual dual indexed libraries
were constructed with 1μg of FFPE genomic DNA for the 53 tumor/normal
pairs using the Accel-NGS 2S Plus Library Kit (Swift, MI, USA). Samples were
fragmented on the Covaris LE220 instrument with 350bp target insert size.
PCR cycle optimization was performed to prevent over-ampliﬁcation of the
libraries. The concentration of each library was determined through qPCR
(Kapa Biosystems, MA, USA). For the normal samples, each library was
loaded on one lane of a HiSeqX ﬂow cell, whereas for tumor samples, each
library was loaded across two lanes of a HiSeqX ﬂow cell. 2×150 paired-end
sequence data were generated at a target depth of 30×(normal) and 60
(tumor) haploid genome coverage. All sequencing data are available in
EGA under accession “EGAS00001002685”. Further details are provided in
the Supplementary Methods.
Tumor heterogeneity
To quantify the level of intra-tumor heterogeneity present in a sample, we
used the MATH score as previously described9;
MATH ¼ MAD VAFsð Þ
median VAFsð Þ
where MAD(VAFs) is the median absolute deviation of the variant allele
fractions (VAFs) of all the mutations (coding and noncoding) in a tumor.
Mutational signature
All samples were analyzed using deconstructSigs26 to extract signatures
based on the Wellcome Trust Sanger Institute Mutational Signature
Framework.
Statistical analysis and survival analysis
Except for age and date of diagnosis that were considered as continuous
variables and therefore compared using the non-parametric
Mann–Whitney U test, differences in other clinicopathological character-
istics between BCP and controls were analyzed using the χ2 test or the
Fisher exact test when appropriate. All statistical tests comparing BCP and
controls were done using the non-parametric Mann–Whitney U test and
the Fisher exact test for continuous and categorical variables, respectively.
Independent association between continuous and binary variables with
BCP vs. controls was investigated using linear and logistic regressions,
respectively. All multivariate tests were adjusted for age at diagnosis, date
of diagnosis, pathological stage, and molecular subtypes by IHC. All
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interaction and multivariate tests were done using analysis of variance to
compare the models with and without the extra term.
All correlations were measured using the non-parametric Spearman’s
rho coefﬁcient. Reported P-values were two-tailed, and differences were
considered signiﬁcant when the P-value was less than 0.05. When
applicable, multiple testing correction was done using the false discovery
rate method (FDR),27 FDR below 0.05 being considered signiﬁcant. All
analyses were done in R software version 3.3.2 (available at www.r-project.
org) and Bioconductor version 3.4.
Survival endpoint was DFS and calculated from the date of surgery to
any loco-regional or distant recurrence, contralateral BC, other primary
tumor or death from any cause, whichever occurred ﬁrst. In the absence of
any of the above-mentioned events, survival was censored at the last
follow-up visit or phone call with the patient. Survival curves were
estimated using the Kaplan–Meier method and compared by the log-rank
test. The prognostic impact of pregnancy on survival was evaluated using
univariate and multivariate Cox proportional hazards regression models
and expressed as hazard ratio (HR) with 95% CI. Multivariate analysis was
adjusted for standard clinical prognostic factors (age at diagnosis, date of
diagnosis, pathological stage, and molecular subtypes by IHC). Further
details are provided in the Supplementary Methods.
Data availability
Raw gene expression data, together with patients’ characteristics, are
publicly available on GEO http://www.ncbi.nlm.nih.gov/geo/, under
accession number GSE53031. Sequencing data have been deposited at
the European Genome-Phenome Archive (http://www.ebi.ac.uk/ega/),
under accession number EGAS00001002685.
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